{"component": "clause", "props": {"groups": [{"samples": [{"hash": "l5NB1Y4c6v4", "uri": "/contracts/l5NB1Y4c6v4#development-activities", "label": "Lease Agreement (Facebook Inc)", "score": 23.1026687622, "published": true}, {"hash": "62zgzk2Hku6", "uri": "/contracts/62zgzk2Hku6#development-activities", "label": "Purchase Agreement (Arena Pharmaceuticals Inc)", "score": 19.0, "published": true}], "snippet": "Seller shall not take any actions with respect to the development of the Property, including, without limitation, applying for, pursuing, accepting or obtaining any permits, approvals or other development entitlements from any governmental or other regulatory entities or finalizing or entering into any agreements relating thereto without Buyer\u2019s prior written consent (which consent may be withheld in Buyer\u2019s sole and absolute discretion).", "snippet_links": [{"key": "seller-shall", "type": "clause", "offset": [0, 12]}, {"key": "with-respect-to", "type": "clause", "offset": [34, 49]}, {"key": "development-of-the-property", "type": "clause", "offset": [54, 81]}, {"key": "without-limitation", "type": "clause", "offset": [94, 112]}, {"key": "development-entitlements", "type": "definition", "offset": [193, 217]}, {"key": "regulatory-entities", "type": "definition", "offset": [249, 268]}, {"key": "entering-into", "type": "clause", "offset": [286, 299]}, {"key": "without-buyer", "type": "clause", "offset": [332, 345]}, {"key": "prior-written-consent", "type": "clause", "offset": [348, 369]}, {"key": "sole-and-absolute-discretion", "type": "definition", "offset": [412, 440]}], "size": 9, "hash": "cadfb08d54b39f8c29156fffb0da0642", "id": 4}, {"samples": [{"hash": "hpocfi8s7s3", "uri": "/contracts/hpocfi8s7s3#development-activities", "label": "License and Development Agreement (Hana Biosciences Inc)", "score": 18.0, "published": true}, {"hash": "fA8VpISIcJ8", "uri": "/contracts/fA8VpISIcJ8#development-activities", "label": "License and Development Agreement (Hana Biosciences Inc)", "score": 18.0, "published": true}, {"hash": "3GoqkgJU0nj", "uri": "/contracts/3GoqkgJU0nj#development-activities", "label": "License and Development Agreement (Hana Biosciences Inc)", "score": 18.0, "published": true}], "snippet": "NovaDel shall not be required to commence any Development Activities until Licensee has executed 100% of the non-refundable License Fee & Equity transaction described in Section 4.4.", "snippet_links": [{"key": "the-non", "type": "clause", "offset": [105, 112]}, {"key": "license-fee", "type": "clause", "offset": [124, 135]}, {"key": "equity-transaction", "type": "definition", "offset": [138, 156]}, {"key": "section-44", "type": "clause", "offset": [170, 181]}], "size": 8, "hash": "3198f24db521519ac7406ad84d2bb9a3", "id": 5}, {"samples": [{"hash": "f7lKat6vhI8", "uri": "/contracts/f7lKat6vhI8#development-activities", "label": "Hope Vi Revitalization Grant Agreement", "score": 24.3552360535, "published": true}, {"hash": "ccPk1YmsbYh", "uri": "/contracts/ccPk1YmsbYh#development-activities", "label": "Grant Agreement", "score": 22.1704311371, "published": true}, {"hash": "gwUO6apZDy7", "uri": "/contracts/gwUO6apZDy7#development-activities", "label": "Hope Vi Revitalization Grant Agreement", "score": 19.0, "published": true}], "snippet": "(1) For any standard (non-mixed finance) public housing development activity under the Revitalization Plan (whether on-site reconstruction or off-site development), the Grantee must obtain HUD approval of a development proposal submitted under 24 CFR part 941 (or successor part), as this part may be amended from time to time (\"Standard Development Proposal\").\n(2) For mixed-finance housing development under the Revitalization Plan, the Grantee must obtain HUD approval of a mixed finance proposal submitted under 24 CFR part 941, subpart F (or successor part and subpart), as may be amended from time to time (\u201cMixed Finance Development Proposal\").\n(3) For new construction of community facilities primarily intended to facilitate the delivery of community and supportive services for residents of the Development and residents of off-site replacement housing, the Grantee must comply with 24 CFR part 941 (or successor part) as this part may be amended from time to time. Information required for this activity must be included in either a Standard or Mixed Finance Development Proposal.", "snippet_links": [{"key": "development-activity", "type": "clause", "offset": [56, 76]}, {"key": "revitalization-plan", "type": "definition", "offset": [87, 106]}, {"key": "site-development", "type": "clause", "offset": [146, 162]}, {"key": "grantee-must", "type": "clause", "offset": [169, 181]}, {"key": "approval-of", "type": "definition", "offset": [193, 204]}, {"key": "development-proposal", "type": "clause", "offset": [207, 227]}, {"key": "cfr-part", "type": "clause", "offset": [247, 255]}, {"key": "from-time-to-time", "type": "clause", "offset": [309, 326]}, {"key": "standard-development", "type": "clause", "offset": [329, 349]}, {"key": "subpart-f", "type": "clause", "offset": [533, 542]}, {"key": "mixed-finance-development", "type": "clause", "offset": [614, 639]}, {"key": "construction-of", "type": "clause", "offset": [664, 679]}, {"key": "community-facilities", "type": "definition", "offset": [680, 700]}, {"key": "delivery-of", "type": "clause", "offset": [738, 749]}, {"key": "services-for", "type": "clause", "offset": [775, 787]}, {"key": "the-development", "type": "clause", "offset": [801, 816]}, {"key": "replacement-housing", "type": "definition", "offset": [843, 862]}, {"key": "comply-with", "type": "definition", "offset": [881, 892]}, {"key": "information-required", "type": "clause", "offset": [976, 996]}], "size": 10, "hash": "d4929b08bdc0cfa9d65479e97f8099b0", "id": 3}, {"samples": [{"hash": "l5unatGKA6d", "uri": "/contracts/l5unatGKA6d#development-activities", "label": "Production Sharing Agreement", "score": 25.4736480713, "published": true}, {"hash": "2Gd2ddtWiwe", "uri": "/contracts/2Gd2ddtWiwe#development-activities", "label": "Production Sharing Agreement", "score": 25.3189601898, "published": true}, {"hash": "j6obn0uSCN2", "uri": "/contracts/j6obn0uSCN2#development-activities", "label": "Production Sharing Agreement", "score": 25.3175907135, "published": true}], "snippet": "The Development activities referred to in item \u201cb\u201d of paragraph 3.1 include:", "snippet_links": [{"key": "the-development", "type": "clause", "offset": [0, 15]}], "size": 16, "hash": "2dc8a967723180f16369be56c8b2260c", "id": 2}, {"samples": [{"hash": "W8LYuUGA2v", "uri": "/contracts/W8LYuUGA2v#development-activities", "label": "Production Sharing Agreement", "score": 27.1436691284, "published": true}, {"hash": "3ublqI3GZHM", "uri": "/contracts/3ublqI3GZHM#development-activities", "label": "Production Sharing Agreement", "score": 23.3189601898, "published": true}, {"hash": "ln2DT8f3x2y", "uri": "/contracts/ln2DT8f3x2y#development-activities", "label": "Production Sharing Agreement", "score": 23.3175907135, "published": true}], "snippet": "The Development activities referred to in item \u201cb\u201d of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection \u2587\u2587\u2587\u2587\u2587; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item \u201cc\u201d includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.", "snippet_links": [{"key": "the-development", "type": "clause", "offset": [0, 15]}, {"key": "production-facilities", "type": "definition", "offset": [123, 144]}, {"key": "completion-of-the", "type": "clause", "offset": [159, 176]}, {"key": "installation-of-equipment", "type": "clause", "offset": [212, 237]}, {"key": "transfer-of", "type": "definition", "offset": [302, 313]}, {"key": "the-installation", "type": "clause", "offset": [327, 343]}, {"key": "not-limited", "type": "clause", "offset": [385, 396]}, {"key": "offshore-platforms", "type": "definition", "offset": [401, 419]}, {"key": "gas-treatment", "type": "definition", "offset": [440, 453]}, {"key": "equipment-and-facilities", "type": "clause", "offset": [462, 486]}, {"key": "measurement-of", "type": "clause", "offset": [491, 505]}, {"key": "wellhead-equipment", "type": "definition", "offset": [532, 550]}, {"key": "flow-lines", "type": "definition", "offset": [570, 580]}, {"key": "and-other-facilities", "type": "clause", "offset": [589, 609]}, {"key": "oil-and-gas-pipelines", "type": "clause", "offset": [658, 679]}, {"key": "pumping-stations", "type": "clause", "offset": [739, 755]}], "size": 17, "hash": "ea6b22588b6b9a64895bb7232d5e3f5d", "id": 1}, {"samples": [{"hash": "EOBTH1dGz7", "uri": "/contracts/EOBTH1dGz7#development-activities", "label": "Revolving Credit Agreement (Kilroy Realty Corp)", "score": 18.0, "published": true}, {"hash": "11n1FzWZGXE", "uri": "/contracts/11n1FzWZGXE#development-activities", "label": "Credit Agreement (Kilroy Realty Corp)", "score": 18.0, "published": true}], "snippet": "The Borrower shall not engage ---------------------- in any development activities except for development in connection with the expansion and/or repositioning or restoration following a casualty or condemnation of existing improvements on Real Property Assets. Notwithstanding the foregoing, the Borrower may engage in all other development activities where there is construction completion risk provided that in no event shall the value (determined in accordance with the book value thereof, in accordance with GAAP) of the Real Property Assets under such other type of development exceed twenty percent (20%) of the Borrower's Total Asset Value.", "snippet_links": [{"key": "the-borrower-shall", "type": "clause", "offset": [0, 18]}, {"key": "for-development", "type": "clause", "offset": [90, 105]}, {"key": "in-connection-with", "type": "clause", "offset": [106, 124]}, {"key": "casualty-or-condemnation", "type": "clause", "offset": [187, 211]}, {"key": "existing-improvements", "type": "definition", "offset": [215, 236]}, {"key": "real-property-assets", "type": "definition", "offset": [240, 260]}, {"key": "notwithstanding-the-foregoing", "type": "clause", "offset": [262, 291]}, {"key": "other-development-activities", "type": "clause", "offset": [324, 352]}, {"key": "construction-completion", "type": "clause", "offset": [368, 391]}, {"key": "provided-that", "type": "clause", "offset": [397, 410]}, {"key": "in-no-event-shall", "type": "clause", "offset": [411, 428]}, {"key": "the-value", "type": "clause", "offset": [429, 438]}, {"key": "in-accordance-with", "type": "definition", "offset": [451, 469]}, {"key": "book-value", "type": "definition", "offset": [474, 484]}, {"key": "the-real-property", "type": "clause", "offset": [522, 539]}, {"key": "type-of-development", "type": "clause", "offset": [564, 583]}, {"key": "of-the-borrower", "type": "clause", "offset": [612, 627]}, {"key": "total-asset-value", "type": "clause", "offset": [630, 647]}], "size": 8, "hash": "aaadb114a3b3daab91472ac6ca705232", "id": 6}, {"samples": [{"hash": "jAbAvLYyYcZ", "uri": "/contracts/jAbAvLYyYcZ#development-activities", "label": "Distribution Agreement (Coherus BioSciences, Inc.)", "score": 25.7310066223, "published": true}, {"hash": "2zXNQgCF0ph", "uri": "/contracts/2zXNQgCF0ph#development-activities", "label": "Distribution Agreement (Coherus BioSciences, Inc.)", "score": 25.591375351, "published": true}], "snippet": "[***] shall have the sole responsibility for conducting development of the Products, including, without limitation, Clinical Trials related to the Products, whether within or outside the Territory. In addition, (a) Coherus and Distributor shall consult with Regulatory Authorities in [***] prior to initiation of the first Phase 3 Clinical Trial for the Product anywhere in the world with respect to the need to include patients from [***] in any Phase 3 Clinical Trial; (b) [***] will use Commercially Reasonable Efforts to include the number of patients from [***] required by the applicable Regulatory Authorities to be included in any Phase 3 Clinical Trial conducted by or on behalf of Coherus[***]; (c) if additional Clinical Trials are required by any Regulatory Authority in connection with (e.g., Phase 4 Clinical Trials) or following receipt of Regulatory Approval, other than Additional Manufacturing Studies (as defined below) (\u201cAdditional Required Clinical Trials\u201d), Coherus shall consult in good faith with Distributor on the feasibility of conducting such Additional Required Clinical Trials ([***]); (d) [***] shall retain final decision-making on whether to proceed with any such Additional Required Clinical Trials unless [***] agrees to pay for any such Additional Required Clinical Trials, in which case [***] shall use Commercially Reasonable Efforts to conduct such Additional Required Clinical Trials and [***] shall promptly pay any invoices submitted by Coherus related to such Additional Required Clinical Trials; (e) if, in connection with the implementation of any [***] and such [***] are not also required outside the Territory, Coherus shall consult in good faith with Distributor on the feasibility of conducting such [***]); (f) Coherus and Distributor shall consult with Regulatory Authorities in [***] prior to initiation of such [***]; (g) if [***], then [***]; and (h) [***] shall retain final decision-making on whether to proceed with any such [***] for the Territory unless [***] agrees to pay for any such [***] for the Territory in which case [***] shall use Commercially Reasonable Efforts to conduct such [***] for the Territory, [***] shall promptly pay any invoices submitted by [***] related to such [***] and, [***]. [***] shall, on [***] reasonable request, provide assistance to [***] in conducting development of the Products in the [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. EXECUTION COPY Territory, including without limitation, any Additional Required Clinical Trials or any [***].", "snippet_links": [{"key": "responsibility-for", "type": "clause", "offset": [26, 44]}, {"key": "development-of-the-products", "type": "clause", "offset": [56, 83]}, {"key": "related-to", "type": "clause", "offset": [132, 142]}, {"key": "outside-the-territory", "type": "clause", "offset": [175, 196]}, {"key": "in-addition", "type": "clause", "offset": [198, 209]}, {"key": "prior-to", "type": "clause", "offset": [290, 298]}, {"key": "initiation-of-the", "type": "clause", "offset": [299, 316]}, {"key": "phase-3-clinical-trial", "type": "clause", "offset": [323, 345]}, {"key": "the-world", "type": "definition", "offset": [374, 383]}, {"key": "with-respect-to", "type": "clause", "offset": [384, 399]}, {"key": "use-commercially-reasonable-efforts", "type": "clause", "offset": [486, 521]}, {"key": "number-of-patients", "type": "clause", "offset": [537, 555]}, {"key": "required-by", "type": "definition", "offset": [567, 578]}, {"key": "applicable-regulatory-authorities", "type": "definition", "offset": [583, 616]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [672, 690]}, {"key": "additional-clinical-trials", "type": "clause", "offset": [712, 738]}, {"key": "regulatory-authority", "type": "definition", "offset": [759, 779]}, {"key": "in-connection-with", "type": "clause", "offset": [780, 798]}, {"key": "phase-4", "type": "definition", "offset": [806, 813]}, {"key": "receipt-of-regulatory-approval", "type": "clause", "offset": [844, 874]}, {"key": "additional-manufacturing", "type": "clause", "offset": [887, 911]}, {"key": "in-good-faith", "type": "definition", "offset": [1002, 1015]}, {"key": "final-decision", "type": "definition", "offset": [1139, 1153]}, {"key": "pay-for", "type": "clause", "offset": [1256, 1263]}, {"key": "submitted-by", "type": "definition", "offset": [1466, 1478]}, {"key": "reasonable-request", "type": "definition", "offset": [2287, 2305]}, {"key": "assistance-to", "type": "clause", "offset": [2315, 2328]}, {"key": "certain-information", "type": "clause", "offset": [2390, 2409]}, {"key": "omitted-and-filed-separately-with-the-securities-and-exchange-commission", "type": "clause", "offset": [2436, 2508]}, {"key": "confidential-treatment", "type": "clause", "offset": [2510, 2532]}, {"key": "execution-copy", "type": "clause", "offset": [2590, 2604]}, {"key": "including-without-limitation", "type": "clause", "offset": [2616, 2644]}], "size": 8, "hash": "58064df6ffc1b879d42b386c6bb7d164", "id": 7}, {"samples": [{"hash": "eOHNf7VQ7h", "uri": "/contracts/eOHNf7VQ7h#development-activities", "label": "Discovery and Development Collaboration and License Agreement (Agios Pharmaceuticals Inc)", "score": 24.5373039246, "published": true}, {"hash": "l05FZWq4Fem", "uri": "/contracts/l05FZWq4Fem#development-activities", "label": "Discovery and Development Collaboration and License Agreement (Agios Pharmaceuticals Inc)", "score": 24.4387397766, "published": true}], "snippet": "(i) The Commercializing Party shall be responsible for conducting all Development activities as may be contemplated under the Development Plan for each Split Program with respect to such Commercializing Party\u2019s portion of the Territory (i.e., the US Territory for Agios and the ROW Territory for Celgene). Neither Commercializing Party shall conduct any Development activities for any Split Program outside such Party\u2019s portion of the Territory (even if such Development activities are for purposes of Development in such Party\u2019s portion of the Territory), unless the JDC by Mutual Consent approves of such activities, including any protocol associated with a Clinical Trial, and such activities are reflected in the applicable Development Plan.\n(ii) The Parties will share all Global Development Costs in accordance with Section 9.4(b); provided that Celgene shall not be responsible for any of Agios\u2019 Global Development Costs prior to the Development Cost Initiation Date. For clarity, Celgene\u2019s obligation to share Global Development Costs shall not include any Development Costs incurred prior to the Development Cost Initiation Date or any Development Costs related to any Clinical Trial for which the FPD occurred prior to the Development Cost Initiation Date even if completed following the Development Cost Initiation Date; instead, Celgene\u2019s obligations will be limited to Development activities related to any company-sponsored Phase II Studies or later stages of Development.\n(iii) If either Party proposes to undertake any Development activities for a Split Program in such Party\u2019s portion of the Territory that the other Party reasonably determines are reasonably likely to have a material adverse impact on the Development or Commercialization of Split Compounds or Split Products in the other Party\u2019s portion of the Territory, such proposing Party shall not proceed with such Development activities unless approved by the JDC (with any disputes resolved in accordance with the dispute resolution procedure of Section 2.8, including the Lead Party having the final decision-making authority to the extent provided in Section 2.8(b)).\n(iv) With respect to each Split Program, each Party shall be entitled to use the data and results (including clinical data) from all Development activities conducted by the other Party; provided that a Party shall not interpret such data or results in a different manner than the Party who performed the Development activity giving rise to the data or results without the performing Party\u2019s prior written consent (which may be given through the Party\u2019s representatives on the JDC). In furtherance thereof, each Commercializing Party shall update the other Party pursuant to Section 3.8(c) on the status of all Development activities for Split Programs, including a summary of relevant data. Each Commercializing Party will use Commercially Reasonable Efforts to ensure the other Party has access to such data and results, including, if appropriate, providing for such access in any agreement with a Third Party Contractor.", "snippet_links": [{"key": "commercializing-party", "type": "definition", "offset": [8, 29]}, {"key": "responsible-for", "type": "clause", "offset": [39, 54]}, {"key": "the-development-plan", "type": "clause", "offset": [122, 142]}, {"key": "with-respect-to", "type": "clause", "offset": [166, 181]}, {"key": "the-territory", "type": "clause", "offset": [222, 235]}, {"key": "us-territory", "type": "clause", "offset": [247, 259]}, {"key": "row-territory", "type": "definition", "offset": [278, 291]}, {"key": "such-party", "type": "clause", "offset": [407, 417]}, {"key": "for-purposes-of", "type": "clause", "offset": [486, 501]}, {"key": "the-jdc", "type": "clause", "offset": [564, 571]}, {"key": "by-mutual-consent", "type": "clause", "offset": [572, 589]}, {"key": "associated-with", "type": "definition", "offset": [642, 657]}, {"key": "clinical-trial", "type": "definition", "offset": [660, 674]}, {"key": "applicable-development", "type": "definition", "offset": [717, 739]}, {"key": "the-parties-will", "type": "clause", "offset": [751, 767]}, {"key": "global-development-costs", "type": "definition", "offset": [778, 802]}, {"key": "in-accordance-with", "type": "definition", "offset": [803, 821]}, {"key": "provided-that", "type": "clause", "offset": [838, 851]}, {"key": "prior-to-the", "type": "clause", "offset": [928, 940]}, {"key": "initiation-date", "type": "definition", "offset": [958, 973]}, {"key": "for-clarity", "type": "clause", "offset": [975, 986]}, {"key": "obligation-to", "type": "clause", "offset": [998, 1011]}, {"key": "development-costs-incurred", "type": "clause", "offset": [1065, 1091]}, {"key": "following-the", "type": "definition", "offset": [1284, 1297]}, {"key": "to-development", "type": "clause", "offset": [1379, 1393]}, {"key": "activities-related-to", "type": "clause", "offset": [1394, 1415]}, {"key": "phase-ii-studies", "type": "definition", "offset": [1438, 1454]}, {"key": "if-either-party", "type": "clause", "offset": [1493, 1508]}, {"key": "other-party", "type": "definition", "offset": [1628, 1639]}, {"key": "likely-to-have", "type": "clause", "offset": [1677, 1691]}, {"key": "material-adverse-impact", "type": "definition", "offset": [1694, 1717]}, {"key": "proposing-party", "type": "definition", "offset": [1847, 1862]}, {"key": "approved-by", "type": "definition", "offset": [1921, 1932]}, {"key": "disputes-resolved", "type": "clause", "offset": [1951, 1968]}, {"key": "dispute-resolution-procedure", "type": "clause", "offset": [1992, 2020]}, {"key": "lead-party", "type": "definition", "offset": [2051, 2061]}, {"key": "final-decision", "type": "definition", "offset": [2073, 2087]}, {"key": "to-the-extent", "type": "clause", "offset": [2105, 2118]}, {"key": "each-party", "type": "definition", "offset": [2189, 2199]}, {"key": "data-and-results", "type": "clause", "offset": [2229, 2245]}, {"key": "clinical-data", "type": "definition", "offset": [2257, 2270]}, {"key": "a-party", "type": "clause", "offset": [2348, 2355]}, {"key": "the-party", "type": "clause", "offset": [2424, 2433]}, {"key": "development-activity", "type": "clause", "offset": [2452, 2472]}, {"key": "performing-party", "type": "definition", "offset": [2520, 2536]}, {"key": "prior-written-consent", "type": "clause", "offset": [2539, 2560]}, {"key": "pursuant-to-section", "type": "definition", "offset": [2710, 2729]}, {"key": "status-of", "type": "clause", "offset": [2744, 2753]}, {"key": "relevant-data", "type": "definition", "offset": [2824, 2837]}, {"key": "use-commercially-reasonable-efforts", "type": "clause", "offset": [2871, 2906]}, {"key": "to-ensure", "type": "clause", "offset": [2907, 2916]}, {"key": "access-to", "type": "definition", "offset": [2937, 2946]}, {"key": "third-party-contractor", "type": "definition", "offset": [3047, 3069]}], "size": 7, "hash": "fbd129671a591e712f2b0431ea4800e2", "id": 8}, {"samples": [{"hash": "4rMuIvIgtdq", "uri": "/contracts/4rMuIvIgtdq#development-activities", "label": "Intergovernmental Agreement", "score": 33.0180587769, "published": true}, {"hash": "gA4HcFZ8B3m", "uri": "/contracts/gA4HcFZ8B3m#development-activities", "label": "Intergovernmental Agreement", "score": 32.8291816711, "published": true}, {"hash": "7spTgIb79QG", "uri": "/contracts/7spTgIb79QG#development-activities", "label": "Intergovernmental Agreement", "score": 32.7325210571, "published": true}], "snippet": "In consideration of the payments and appropriations made by the City under this Agreement, and the other promises and commitments made hereunder, the URA agrees that it shall undertake the following activities whenever and wherever needed in the City, in coordination and cooperation with the City:\n1. The URA may enter into and execute any contracts, leases, mortgages, or other agreements, including agreements with bondholders or lenders, determined by the URA to be necessary or convenient to implement the provisions and effectuate the purposes of this Agreement. All such contracts, leases, mortgages, or other agreements which impose upon the URA any monetary obligation which cannot be satisfied without money from the City\u2019s budget shall be approved by the City prior to being entered into by the URA.\n2. From time to time, the URA may acquire property, real or personal, or interests therein, for redevelopment and development purposes, and use or dispose of such property or interests, either through the City or directly with private parties.\n3. The URA may conduct other planning and implementation activities as are deemed necessary and prudent, including planning and predevelopment activities such as site analysis, environmental analysis, development planning, market analysis, financial feasibility studies, preliminary design, zoning compliance, facilities inspections, and overall analysis of proposed redevelopment plans to ensure consistency with the City's overall goals and short term and long-range plans.", "snippet_links": [{"key": "in-consideration-of-the", "type": "clause", "offset": [0, 23]}, {"key": "by-the-city", "type": "clause", "offset": [57, 68]}, {"key": "other-promises", "type": "clause", "offset": [99, 113]}, {"key": "in-the-city", "type": "definition", "offset": [239, 250]}, {"key": "cooperation-with-the", "type": "clause", "offset": [272, 292]}, {"key": "other-agreements", "type": "definition", "offset": [374, 390]}, {"key": "the-provisions", "type": "clause", "offset": [507, 521]}, {"key": "the-purposes-of-this-agreement", "type": "clause", "offset": [537, 567]}, {"key": "monetary-obligation", "type": "clause", "offset": [658, 677]}, {"key": "approved-by", "type": "definition", "offset": [750, 761]}, {"key": "prior-to", "type": "clause", "offset": [771, 779]}, {"key": "entered-into", "type": "clause", "offset": [786, 798]}, {"key": "from-time-to-time", "type": "clause", "offset": [814, 831]}, {"key": "acquire-property", "type": "clause", "offset": [845, 861]}, {"key": "development-purposes", "type": "definition", "offset": [925, 945]}, {"key": "dispose-of", "type": "definition", "offset": [958, 968]}, {"key": "private-parties", "type": "clause", "offset": [1038, 1053]}, {"key": "implementation-activities", "type": "clause", "offset": [1097, 1122]}, {"key": "deemed-necessary", "type": "definition", "offset": [1130, 1146]}, {"key": "predevelopment-activities", "type": "clause", "offset": [1183, 1208]}, {"key": "site-analysis", "type": "clause", "offset": [1217, 1230]}, {"key": "environmental-analysis", "type": "clause", "offset": [1232, 1254]}, {"key": "development-planning", "type": "clause", "offset": [1256, 1276]}, {"key": "market-analysis", "type": "definition", "offset": [1278, 1293]}, {"key": "feasibility-studies", "type": "definition", "offset": [1305, 1324]}, {"key": "preliminary-design", "type": "definition", "offset": [1326, 1344]}, {"key": "zoning-compliance", "type": "clause", "offset": [1346, 1363]}, {"key": "redevelopment-plans", "type": "definition", "offset": [1422, 1441]}, {"key": "to-ensure", "type": "clause", "offset": [1442, 1451]}, {"key": "overall-goals", "type": "clause", "offset": [1480, 1493]}, {"key": "short-term", "type": "clause", "offset": [1498, 1508]}], "size": 6, "hash": "de00906cc56c0cd114b4dc3260da27e4", "id": 9}, {"samples": [{"hash": "9GRY3JUkmTM", "uri": "/contracts/9GRY3JUkmTM#development-activities", "label": "License and Collaboration Agreement (Seagen Inc.)", "score": 31.8186168671, "published": true}, {"hash": "klsoJvkwYek", "uri": "/contracts/klsoJvkwYek#development-activities", "label": "License and Collaboration Agreement (Genmab a/S)", "score": 30.4017791748, "published": true}, {"hash": "9IyrDdoXRnW", "uri": "/contracts/9IyrDdoXRnW#development-activities", "label": "License and Collaboration Agreement (Genmab a/S)", "score": 30.2484607697, "published": true}], "snippet": "Each Party shall use Commercially Reasonable Efforts to perform its obligations with respect to the Development of each Collaboration Product in accordance with the latest Joint Development Plan and Joint Budget and all such activities shall be conducted in accordance with all Applicable Laws, including as applicable, GCPs, GLPs and GMPs. As part of such efforts, each Party shall commit the personnel and facilities necessary to carry out its obligations under the latest Joint Development Plan. Neither SGI nor Genmab shall be required to undertake any activity relating to the Development of a Collaboration Product that it believes, in good faith, may violate any Applicable Law. The Parties acknowledge and agree that neither Party guarantees the success of the Development tasks undertaken hereunder.", "snippet_links": [{"key": "each-party", "type": "definition", "offset": [0, 10]}, {"key": "efforts-to-perform", "type": "clause", "offset": [45, 63]}, {"key": "with-respect-to", "type": "clause", "offset": [80, 95]}, {"key": "the-development", "type": "clause", "offset": [96, 111]}, {"key": "collaboration-product", "type": "clause", "offset": [120, 141]}, {"key": "in-accordance-with", "type": "definition", "offset": [142, 160]}, {"key": "joint-development-plan", "type": "clause", "offset": [172, 194]}, {"key": "joint-budget", "type": "definition", "offset": [199, 211]}, {"key": "all-applicable-laws", "type": "definition", "offset": [274, 293]}, {"key": "personnel-and-facilities", "type": "clause", "offset": [394, 418]}, {"key": "obligations-under-the", "type": "clause", "offset": [446, 467]}, {"key": "relating-to", "type": "definition", "offset": [566, 577]}, {"key": "development-of-a", "type": "clause", "offset": [582, 598]}, {"key": "in-good-faith", "type": "definition", "offset": [639, 652]}, {"key": "the-parties-acknowledge-and-agree-that", "type": "clause", "offset": [686, 724]}, {"key": "neither-party", "type": "definition", "offset": [725, 738]}, {"key": "development-tasks", "type": "definition", "offset": [769, 786]}], "size": 5, "hash": "13a6db93d1b10603cea6973ddf903327", "id": 10}], "next_curs": "Cl8SWWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjsLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2Ih9kZXZlbG9wbWVudC1hY3Rpdml0aWVzIzAwMDAwMDBhDKIBAmVuGAAgAA==", "clause": {"parents": [["development", "Development"], ["objectives-under-the-development-plan", "Objectives Under the Development Plan"], ["affirmative-and-negative-covenants", "AFFIRMATIVE AND NEGATIVE COVENANTS"], ["development-and-regulatory-activities", "Development and Regulatory Activities"], ["development-program", "Development Program"]], "title": "Development Activities", "children": [["general", "General"], ["reports", "Reports"], ["development-costs", "Development Costs"], ["regulatory-matters", "Regulatory Matters"], ["clinical-trials", "Clinical Trials"]], "size": 679, "id": "development-activities", "related": [["development-program", "Development Program", "Development Program"], ["development-and-commercialization", "Development and Commercialization", "Development and Commercialization"], ["collaboration-activities", "Collaboration activities", "Collaboration activities"], ["development-plan", "Development Plan", "Development Plan"], ["development-work", "Development Work", "Development Work"]], "related_snippets": [], "updated": "2026-05-15T04:24:17+00:00", "also_ask": ["What key milestones and deliverables should be explicitly defined in the Development Activities clause?", "How can the clause allocate risks for delays, cost overruns, or failure to meet specifications?", "What negotiation leverage points exist regarding approval rights and change management?", "How does this clause compare to industry standards or similar agreements in terms of developer obligations?", "What are the most common enforceability challenges for Development Activities clauses in court?"], "drafting_tip": "Specify permitted development activities to prevent unauthorized actions, define approval processes to ensure oversight, and set timelines to promote project efficiency.", "explanation": "The 'Development Activities' clause defines the scope and parameters of work related to the creation, design, or improvement of a product, service, or project. It typically outlines the specific tasks, milestones, and responsibilities assigned to each party during the development phase, such as timelines for deliverables, quality standards, and reporting requirements. By clearly delineating these activities, the clause ensures that both parties have a mutual understanding of expectations and obligations, thereby reducing the risk of misunderstandings or disputes during the development process."}, "json": true, "cursor": ""}}